Alphamab Oncology Secures China Approval for Dual-Payload ADC JSKN021
Event summary
- Alphamab Oncology received acceptance from the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) for an Investigational New Drug (IND) application for JSKN021.
- JSKN021 is a dual-payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, utilizing glycan-specific conjugation technology.
- Preclinical data presented at the 2025 AACR meeting demonstrated JSKN021’s superior tumor inhibition efficacy compared to single-payload ADCs.
- The Phase I clinical trial will assess safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced malignant solid tumors.
- JSKN021 combines a topoisomerase I inhibitor (T01) and Monomethyl auristatin E (MMAE) payloads, designed to address tumor heterogeneity and resistance.
The big picture
Alphamab Oncology’s advancement of JSKN021 underscores the growing focus on next-generation ADCs with enhanced targeting and payload combinations to overcome treatment resistance in oncology. The acceptance of the IND application positions Alphamab to compete in a rapidly evolving market, particularly within China's expanding biopharmaceutical sector. The company’s existing portfolio, including Envafolimab, provides a foundation for continued innovation and strategic partnerships.
What we're watching
- Clinical Outcomes
- The success of the Phase I trial will hinge on demonstrating acceptable safety and tolerability, alongside preliminary evidence of antitumor activity, which will dictate progression to Phase II.
- Regulatory Pathway
- The NMPA’s review timeline and potential requirements for subsequent clinical phases will be crucial for Alphamab’s commercialization strategy in China.
- Competitive Landscape
- Given the crowded ADC market, Alphamab will need to clearly differentiate JSKN021’s dual-payload approach and demonstrate a significant clinical advantage over existing therapies.
Related topics